<DOC>
	<DOC>NCT00943527</DOC>
	<brief_summary>This study is to examine the effects of menstrual cycle, hormone therapy, and the use of tamoxifen on Tc-99m sestamibi uptake.</brief_summary>
	<brief_title>Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
	<criteria>Arm 1 age 3545 have regular menstrual cycles as defined by having menstrual cycle length of 2531 days, with menstrual flow of 27 days, and no intermenstrual spotting or bleeding. have had a negative screening mammogram within one year prior to the MBI studies that is available for comparison. currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors have a personal history of any cancer, except nonmelanomatous skin cancer unable to understand and sign the consent form pregnant or lactating physically unable to sit upright and still for 30 minutes Arm 2 scheduled to begin one of the following regimens of HT: Any dosage of any formulation of systemic estrogen therapy in the setting of a prior hysterectomy Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the progesterone therapy is the oral, micronized formulation had a negative screening mammogram within one year prior to the MBI studies that is available for comparison. have a personal history of any cancer, except nonmelanomatous skin cancer unable to understand and sign the consent form pregnant or lactating physically unable to sit upright and still for 30 minutes Arm 3 scheduled to begin treatment with tamoxifen Or are currently being treated with tamoxifen (for &gt; 1 month) and have had an MBI scan performed prior to its initiation have had or will have the following test performed at Mayo Clinic: #87966, Cytochrome P450 2D6 genotyping for Tamoxifen Hormonal Therapy have had a screening or diagnostic mammogram within one year of the MBI studies that is available for comparison. are using or have used any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones), any estrogen receptor modulating drugs other than tamoxifen, or any aromatase inhibitors from the time of 1 month prior to the first MBI until completion of the second MBI. have been treated or will be undergoing treatment with systemic chemotherapy or external radiation beam therapy to the breast from the time of 6 months prior to the first MBI until the completion of the second MBI. unable to understand and sign the consent form pregnant or lactating physically unable to sit upright and still for 30 minutes</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Breast</keyword>
	<keyword>Menstrual Cycle</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Hormone</keyword>
	<keyword>MBI</keyword>
	<keyword>Molecular Breast Imaging</keyword>
	<keyword>Breast Imaging</keyword>
</DOC>